Some drugs targeting CSF2RA have been developed to treat autoimmune diseases (sargramostim, KB002), diabetic foot ulcers (foreskin fibroblast), and accelerate wound closure and healing (foreskin keratinocyte). Here, CSF2RA is linked to diabetic foot.